Interleukin-10: a cytokine used by tumors to escape immunosurveillance (original) (raw)

• Burnett FM.Immunological Surveillance. Pergamon Press: Oxford: Pergamon (Australia): Sydney 1970.
  Google Scholar
• Rosenberg SA_et al._ Gene transfer into humans-immuno-therapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.N Engl J Med 1990;323: 570–578.
  Article CAS PubMed Google Scholar
• Arienti F_et al._ Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected_in vitro_ with low doses of IL-2.Cancer Immunol Immunother. 1993;36: 315–322.
  Article CAS PubMed Google Scholar
• Schwartzentruber DJ_et al. In vitro_ predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.J Clin Oncol 1994;12: 1475–1483.
  Article CAS PubMed Google Scholar
• Townsend AR, Gotch FM, Davey J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein.Cell 1985;42: 457–467.
  Article CAS PubMed Google Scholar
• Townsend AR_et al._ The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides.Cell 1986;44: 959–968.
  Article CAS PubMed Google Scholar
• Goldberg AL, Rock KL. Proteolysis, proteasomes and antigen presentation [Review].Nature 1992;357: 375–379.
  Article CAS PubMed Google Scholar
• Spies T_et al._ Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer.Nature 1992;355: 644–646.
  Article CAS PubMed Google Scholar
• Neefjes JJ, Momburg F, Hammerling GJ. Selective and molecules is dependent on a putative peptide transporter heterodimer.Nature 1992;355: 644–646.
  Article Google Scholar
• Koopmann JO, Hammerling GJ, Momburg F. Generation, intracellular transport and loading of peptides associated with MHC class I molecules [Review].Curr Opin Immunol 1997;9: 80–88.
  Article CAS PubMed Google Scholar
• Ljunggren HG_et al._ Molecular analysis of H-2 deficient lymphoma lines: distinct defects in biosynthesis and association of MHC class I heavy chain and b2-microglobulin observed in cells with increased sensitivity to NK cell lysis.J Immunol 1989;142: 2911–2917.
  Article CAS PubMed Google Scholar
• Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes [Review].Ann Rev Immunol 1989;7: 601–624.
  Article CAS Google Scholar
• Cabrera T_et al._ High frequency of altered HLA class I phenotypes in invasive breast carcinomas.Hum Immunol 1996;50: 126–134.
  Article Google Scholar
• Garrido F_et al._ Natural history of HLA expression during tumor development.Immunol Today 1993;14: 491–499.
  Article CAS PubMed Google Scholar
• Cromme FV, Airey J, Heemels MT, Ploegh HL, Walboomers JMM. Loss of transporter protein, encoded by the TAP-2 gene, is highly correlated with loss of HLA expression in cervical carcinomas.J Exp Med 1994;179: 335–340.
  Article CAS PubMed Google Scholar
• Wolfel T_et al._ Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restrict element for three different antigens.J Exp Med 1989;170: 797–810.
  Article CAS PubMed Google Scholar
• Kono K_et al._ Mechanisms of escape from CD8+ T-cell clones specific for the HER-2/neu proto-oncogene expressed in ovarian carcinomas: related and unrelated to decreased MHC class 1 expression.Int J Cancer 1997;70: 112–119.
  Article CAS PubMed Google Scholar
• Ruiz-Cabello F, Klein E, Garrido F. MHC antigens on human tumors [Review].Immunol Lett 1991;29: 181–189.
  Article CAS PubMed Google Scholar
• Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms functional significance and clinical relevance [Review].Immunol Today 1995;16: 487–494.
  Article CAS PubMed Google Scholar
• Lehmann F_et al._ Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection.Eur J Immunol 1995;25: 340–347.
  Article CAS PubMed Google Scholar
• Ikeda H_et al._ Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor.Immunity 1997;6: 199–208.
  Article CAS PubMed Google Scholar
• Seliger B_et al._ Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP and MHC class I expression and their upregulation by IFN-gamma.Scand J Immunol 1997;46: 625–632.
  Article CAS PubMed Google Scholar
• Seliger B_et al._ Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: Evidence for deficiencies asosciated with transformation and progression.Cancer Res 1996;56: 1756–1760.
  CAS PubMed Google Scholar
• Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL, Gatter KC. Loss of antigen-presenting molecules (MHC class I and TAP-1), in lung cancer.Br J Cancer 1996;73: 148–153
  Article CAS PubMed PubMed Central Google Scholar
• Kaklamanis L_et al._ Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer.Am J Pathol 1994;145: 505–509.
  CAS PubMed PubMed Central Google Scholar
• Chen HL_et al._ A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer.Nat Genet 1996;13: 210–213.
  Article CAS PubMed Google Scholar
• Mnich SJ_et al._ Characterization of a monoclonal antibody that neutralizes the activity of prostaglandin E2.J Immunol 1995;155: 4437–4444.
  Article CAS PubMed Google Scholar
• Schrey MP, Patel KV. Protaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators.Br J Cancer 1995;72: 1412–1419.
  Article CAS PubMed PubMed Central Google Scholar
• Klapan I_et al._ Lipid-bound sialic acid, prostaglandin E and histamine in head and neck cancer.Eur J Cancer 1993;29A: 839–845.
  Article CAS PubMed Google Scholar
• Marnett LJ. Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer [Review].Prev Med 1995;24: 103–106.
  Article CAS PubMed Google Scholar
• Arvind P_et al._ Prostaglandin E2 down-regulates the expression of HLA-DR antigen in human colon adeno-carcinoma cell lines.Biochemistry 1995;34: 5604–5609.
  Article CAS PubMed Google Scholar
• Arteaga CL_et al._ Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.J Clin Invest 1993;92: 2569–2576.
  Article CAS PubMed PubMed Central Google Scholar
• Wright JA, Turley EA, Greenberg AH. Transforming growth factor beta and fibroblast growth factor as promoters of tumor progression to malignancy [Review].Crit Rev Oncog 1993;4: 473–492.
  CAS PubMed Google Scholar
• Fakhrai H_et al._ Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy.Proc Natl Acad Sci USA 1996;93: 2909–2914.
  Article CAS PubMed PubMed Central Google Scholar
• Blanckaert VD, Schelling ME, Elstad CA. Differential growth factor production, secretion, and response by high and low metastatic variants of B16BL6 melanoma.Cancer 1993;53: 4075–4081.
  CAS Google Scholar
• Friedman E_et al._ High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer.Cancer Epidemiol Biomark Prev 1995;4: 549–554.
  CAS Google Scholar
• Friess H_et al._ Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival.Gastroenterology 1993;105: 1846–1856.
  Article CAS PubMed Google Scholar
• Steiner MS, Zhou ZZ, Tonb DC, Barrack ER. Expression of transforming growth factor-beta 1 in prostate cancer.Endocrinology 1994;135(5): 2240–2247.
  Article CAS PubMed Google Scholar
• Bottomly K. A functional dichotomy in CD4+ lymphocyte [Review].Immunol Today 1988;9: 268–274.
  Article CAS PubMed Google Scholar
• Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases [Review].Clin Microbiol Rev 1996;9: 532–562.
  Article CAS PubMed PubMed Central Google Scholar
• Sredni B. Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101.J Natl Cancer Inst 1996;88: 1276–1284.
  Article CAS PubMed Google Scholar
• Lowes MA, Bishop GA, Crotty K, Barnetson RS, Halliday GM. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas.J Invest Dermatol 1997;108: 914–919.
  Article CAS PubMed Google Scholar
• Vieira P_et al._ Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI.Proc Natl Acad Sci USA 1991;88: 1172–1176.
  Article CAS PubMed PubMed Central Google Scholar
• MacNeil IA, Suda T, Moore KW, Mosmann TR, Zlotnik A. IL-10, a novel growth cofactor for mature and immature T cells.J Immunol 1990;145: 4167–4173.
  Article CAS PubMed Google Scholar
• Chen WF, Zlotnik A. IL-10: a novel cytotoxic T cell differentiation factor.J Immunol 1991;147: 528–534.
  Article CAS PubMed Google Scholar
• de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.J Exp Med 1991;174: 1209–1220.
  Article PubMed Google Scholar
• Fiorentino DF_et al._ IL-10 inhibits cytokine production by activated macrophages.J Immunol 1991;147: 3815–3822.
  Article CAS PubMed Google Scholar
• Fiorentino DF_et al._ IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.J Immunol 1991;146: 3444–3451.
  Article CAS PubMed Google Scholar
• Taga K, Mostowski H, Tosato G. Human interleukin-10 can directly inhibit T cell growth.Blood 1993;81: 2964–2971.
  Article CAS PubMed Google Scholar
• de waal-Malefyt R_et al._ IL-10 and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II MHC expression.J Exp Med 1991;174: 915–924.
  Article PubMed Google Scholar
• Caux C_et al._ Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells.Int Immunol 1994;6: 1177–1185.
  Article CAS PubMed Google Scholar
• Peguet-Navarro J_et al._ Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells.Eur J Immunol 1994;24: 884–891.
  Article CAS PubMed Google Scholar
• Ding LS, Linsley PS, Huang L-Y, Germain RR, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression.J Immunol 1993;151: 1224–1234.
  Article CAS PubMed Google Scholar
• Gazzinelli RT, Oswald IP, James SL, Sher A. IL-10 inhibits parasite killing and nitric oxide production by IFN-g-activated macrophages.J Immunol 1992;148: 1792–1796.
  Article CAS PubMed Google Scholar
• Hagenbaugh A_et al._ Altered immune responses in interleukin 10 transgenic mice.J Exp Med 1997;185: 2101–2110.
  Article CAS PubMed PubMed Central Google Scholar
• Gastle GA_et al._ Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression.Int J Cancer 1993;55: 96–101.
  Article Google Scholar
• Gotlieb WH_et al._ Presence of interleukin 10 (Il-10) in the ascites of patients with ovarian and other intra-abdominal cancers.Cytokine 1992;4: 385–390.
  Article CAS PubMed Google Scholar
• Pisa P_et al._ Selective expression of interleukin 10, interferon-g and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies.Proc Natl Acad Sci USA 1993;89: 7708–7712.
  Article Google Scholar
• Nakagomi H_et al._ Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma.Int J Cancer 1995;63: 366–371.
  Article CAS PubMed Google Scholar
• Huang M_et al._ Human non-small lung cancer cells express a type 2 cytokine pattern.Cancer Res 1995;55: 3847–3853.
  CAS PubMed Google Scholar
• Kruger-Krasagakes S_et al._ Expression of interleukin 10 in human melanoma.Br J Cancer 1994;70: 1182–1185.
  Article CAS PubMed PubMed Central Google Scholar
• Dummer W_et al._ Interleukin-10 production in malignant melanoma: preferential detection of Il-10-secreting tumor cells in metastatic lesions.Int J Cancer 1996;66: 607–610.
  Article CAS PubMed Google Scholar
• Matsuda M_et al._ Interleukin-10 pre-treatment protects target cells from tumor- and allo-specific cytotoxic T-cells and down-regulates HLA class I expression.J Exp Med 1994;180: 2371–2376.
  Article CAS PubMed Google Scholar
• Yue FY_et al._ Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules.Int J Cancer 1997;71: 630–637.
  Article CAS PubMed Google Scholar
• Ljunggren HG, Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism.J Exp Med 1985;162: 1745–1759.
  Article CAS PubMed Google Scholar
• Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.Nature 1986;319: 675–678.
  Article CAS PubMed Google Scholar
• Powis SJ_et al._ Restoration of antigen presentation to the mutant cell line RMA-S by an MHC-linked transporter.Nature 1991;354: 528–531.
  Article CAS PubMed Google Scholar
• Attaya M_et al._ Ham2 corrects the class I antigen processing defect in RMA-S cells.Nature 1992;355: 647–649.
  Article CAS PubMed Google Scholar
• Ljunggren H-G_et al._ Empty MHC class I molecules come out in the cold.Nature 1990;346: 476–480.
  Article CAS PubMed Google Scholar
• Salazar-Onfray F_et al._ IL-10 converts mouse lymphoma cells to a CTL-resistant, NK sensitive phenotype with low but peptide-inducible MHC class I expression.J Immunol 1995;154: 6291–6298.
  Article CAS PubMed Google Scholar
• Petersson M_et al._ Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression and poor TAP1/2 function in the prototype NK target YAC-1.J Immunol 1998;161: 2099–2105.
  Article CAS PubMed Google Scholar
• Salazar-Onfray F_et al._ Down-regulation of the expression and function of TAP in murine tumor cell lines expressing Interleukin-10.J Immunol 1997;159: 3195–3202.
  Article CAS PubMed Google Scholar
• Kiessling R, Klein E, Pross H, Wigzel H. ‘Natural’ killer cells in the luse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cells.Eur J Immunol 1975;5: 117–121.
  Article CAS PubMed Google Scholar
• Cikes M, Friberg S Jr, Klein G. Progressive loss of H-2 antigen(s) determined by Moloney leukemia virus in cultured murine lymphomas.J Natl Cancer Inst 1973;50: 347–362.
  Article CAS PubMed Google Scholar
• Becker S, Kiessling R, Lee N, Klein G. Modulation of sensitivity to natural killer cell lysis after_in vitro_ explantation of a mouse lymphoma.J Natl Cancer Inst 1978;61: 1495–1498.
  CAS PubMed Google Scholar
• Petersson MG, Karre K, Cochet M, Kourilsky P, Kiessling R. An active T-cell-independent mechanism enhances MHC class I transcription and expression on a mouse T-cell lymphoma_in vivo_.Cell Immunol 1987;108: 460–472.
  Article CAS PubMed Google Scholar
• Richter G_et al._ Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration.Cancer Res 1993;53: 4134–4137.
  CAS PubMed Google Scholar
• Maxwell E_et al. In vivo_ effects of hIL-10 on the growth of various tumors.Proc Am Assoc Cancer Res 1994:35: 480–485.
  Google Scholar
• Giovarelli M_et al._ Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances anti tumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory.J Immunol 1995;155: 3112–3123.
  Article CAS PubMed Google Scholar
• Zheng LM_et al._ Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism.J Exp Med 1996;184: 579–584.
  Article CAS PubMed Google Scholar
• Kundu N, Fulton AM. Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis.Cell Immunol 1997;180: 55–61.
  Article CAS PubMed Google Scholar
• Zeidler R_et al._ Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10.Blood 1997;90: 2390–2397.
  Article CAS PubMed Google Scholar
• Benjamin D, Park CD, Sharma V. Human B cell interleukin 10 [Review].Leuk Lymphoma 1994;12: 205–210.
  Article CAS PubMed Google Scholar
• Lee SP_et al._ Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-Barr virus-specific cytotoxic T-cell recognition.Blood 1998;92: 1020–1030.
  Article CAS PubMed Google Scholar
• Sugita K, Miyazaki JI, Appella E, Ozato K. Interferons increase transcription of a mayor histocompatibility class I gene via a 5 interferon consensus sequence.Mol Cell Biol 1987;7: 2625–2630.
  CAS PubMed PubMed Central Google Scholar
• Ayalon O_et al._ Induction of transporter associated with antigen processing by interferon-gamma confers endothelial cell cytoprotection against natural killer-mediated lysis.Proc Natl Acad Sci USA 1998;95:2435–2440.
  Article CAS PubMed PubMed Central Google Scholar
• Restifo NP, Spiess PJ, Karp SE, Mulé JJ, Rosenberg SA. A nonimmunogenic sarcoma transduced with the cDNA for interferon g elicits CD8+ T cells against the wild type tumor: Correlation with antigen presentation capability.J Exp Med 1992;175: 1423–1431
  Article CAS PubMed Google Scholar
• Hiltbold EM, Ziegler HK. Interferon-gamma and interleukin-10 have cross-regulatory roles in modulating the class I and class II MHC-mediated presentation of epitopes of Listeria monocytogenes by infected macrophages.J Interferon Cytokine Res 1996;16: 547–554.
  Article CAS PubMed Google Scholar
• Hill A_et al._ Herpes simplex virus turns off the TAP to evade host immunity.Nature 1995;375: 411–415.
  Article CAS PubMed Google Scholar
• Fruh K_et al._ A viral inhibitor of peptide transporters for antigen presentation.Nature 1995;375: 415–418.
  Article CAS PubMed Google Scholar
• Rotem-Yehudar R, Groettrup M, Soza A, Kloetzel PM, Ehrlich R. Lmp-associated proteolytic activities and TAP-dependent peptide transport for class I MHC molecules are suppressed in cell lines transformed by the highly oncogenic Adenovirus12.J Exp Med 1996;183: 499–514.
  Article CAS PubMed Google Scholar
• Rotem-Yehudar R, Winograd S, Sela S, Coligan JE, Ehrlich R. Downregulation of peptide transporter genes in cell lines transformed with the highly oncogenic adenovirus 12.J Exp Med 1994;180: 477–488.
  Article CAS PubMed Google Scholar
• Bacchetta R_et al._ High levels of interleukin 10 production_in vivo_ are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells.J Exp Med 1994;179: 493–502.
  Article CAS PubMed Google Scholar
• Rosenberg SA_et al._ Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.Nat Med 1998;4(3): 321–327.
  Article CAS PubMed PubMed Central Google Scholar
• Nestle FO_et al._ Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.Nat Med 1998;4(3): 328–332.
  Article CAS PubMed Google Scholar
• Wang L, Goillot E, Tepper RI. IL-10 inhibits alloreactive cytotoxic T lymphocyte generation_in vivo_.Cell Immunol 1994;159: 152–169.
  Article CAS PubMed Google Scholar
• Suzuki T_et al._ Viral interleukin-10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local energy to allogeneic and syngeneic tumors.J Exp Med 1995;182: 477–486.
  Article CAS PubMed Google Scholar